All In Biotech

Drug Trial Radar · NCT07169994

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Multi-center, Open-Label, Phase Ib/II Study of YL202 in Combination With Anti-tumor Therapy to Evaluate the Safety, Tolerability, and Efficacy in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

414

Planned (sponsor's estimate)

Start

Sep 2, 2025

Primary completion

Sep 1, 2026

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumors
  • Breast Cancer
  • Non Small Cell Lung Cancer

Interventions

  • YL202 for injection; Toripalimab injectionDrug

    Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab

  • YL202 for injection; Furmonertinib Mesilate TabletsDrug

    Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nature and frequency of dose-limiting toxicity (DLT)Time frame: 21 days after the first dose was administered to each subject.
  2. Nature and frequency of adverse events (AEs)Time frame: 42 days after the end of treatment (EOT).

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)

    Hefei, Anhui, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Meizhou People's Hospital(Huangtang Hospital)Meizhou Academy of Medical Sciences

    Meizhou, Guangdong, China · Not yet recruiting

  • Ghang xi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Affiliated Hospital Of Hebei University

    Baoding, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Anyang Cancer Hospital

    Anyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • The First People's Hospital of Changde City

    Changde, Hunan, China · Not yet recruiting

  • Jiangsu Province Hospital(The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Affiliated Zhongshan Hospital Dalian University

    Dalian, Liaoning, China · Not yet recruiting

  • Liaoning cancer hospital &institute

    Shenyang, Liaoning, China · Not yet recruiting

  • Affiliated Zhongshan Hospital Dalian University

    Jinan, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital

    Sichuan, Sichuan, China · Not yet recruiting

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.